- Home
- Products
ATRIANCE (Nelarabine)
ATRIANCE (Nelarabine)
- Medicine Name: Atriance
- Generic Name: Nelarabine
- Dosage Form & Strength: Injection – 250 mg/50 mL (5 mg/mL)
- Manufactured By: Novartis
Atriance (Nelarabine) is a chemotherapy medicine classified as a nucleoside metabolic inhibitor. It is FDA-approved for use in the treatment of:
- T-cell acute lymphoblastic leukemia (T-ALL)
- T-cell lymphoblastic lymphoma (T-LBL)
It is prescribed for patients whose disease has not responded to, or has relapsed after, treatment with at least two chemotherapy regimens.
Dosage Guidelines:
- Adults and adolescents (16 years and older): 1500 mg/m² intravenously over 2 hours on Days 1, 3, and 5. The cycle repeats every 21 days.
- Children and adolescents (21 years and younger): 650 mg/m² intravenously over 1 hour for 5 consecutive days. Cycle repeated every 21 days.
These regimens aim to optimize efficacy while minimizing side effects.
- Monitor for neurological side effects such as seizures, confusion, and peripheral neuropathy. Treatment interruption may be required if symptoms become severe.
- Avoid live vaccines during and after treatment to reduce infection risk.
- Regularly monitor blood counts, including neutrophils, platelets, and red blood cells, to manage potential cytopenias.
- Be alert to signs of tumor lysis syndrome (TLS). Monitor electrolyte levels and initiate hydration or allopurinol if needed.
- Atriance may be harmful to a developing fetus. Women of reproductive potential should use effective contraception and undergo pregnancy testing before treatment.
To import Atriance (Nelarabine) via GlobalRareMeds, the following documents are required:
- Valid prescription from a licensed medical practitioner
- Diagnostic reports
- Government-issued patient ID
Order Confirmation:
The order will be processed only after receipt of valid prescription and, if applicable, an import permit.
Atriance (Nelarabine) is a regulated prescription drug and may be imported only under named-patient protocols in countries where it is not yet commercially available.
GlobalRareMeds ensures the reliable sourcing of Atriance (Nelarabine) through licensed international suppliers. We help deliver this medication in compliance with applicable laws, offering access across regions including:
- India and SAARC countries: Afghanistan, Nepal, Bhutan, Bangladesh, Maldives, Pakistan, Sri Lanka
- Select Gulf countries: UAE, Saudi Arabia, Bahrain, Oman, Qatar, Kuwait, Iraq
Orders are dispatched from our fulfillment center in Ambernath, Thane District, after pharmacist review and documentation verification.
Contact Us:
📧 Email: info@globalraremeds.com
📞 Call/WhatsApp: +91-99675 15602
Q. What is the generic name of Atriance?
A. The generic name is Nelarabine.
Q. Who manufactures Atriance?
A. Atriance is manufactured by Novartis.
Q. Is Atriance FDA approved?
A. Yes, Atriance was approved by the FDA in October 2005.
Q. What form and strength is Atriance available in?
A. Atriance is supplied as an intravenous injection: 250 mg/50 mL (5 mg/mL).
Q. What are the common side effects?
A. Common side effects may include nausea, fatigue, headache, tingling or numbness, blurred vision, constipation, and drowsiness.
Q. How can I buy Atriance (Nelarabine) in India?
A. You can request Atriance via GlobalRareMeds. We facilitate access based on valid medical prescriptions.
Q. Is Atriance available in SAARC or Gulf countries?
A. Yes, Atriance can be supplied to both SAARC and Gulf countries, subject to local import regulations.
Q. What are the storage requirements for Atriance?
A. Store at 20–25°C (68–77°F) in original packaging. Protect from light and moisture.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
